Note on the Development and Use of Liquid Biopsy Technology
2021 | Case No. E766 | Length 23 pgs.
This case details the introduction of liquid biopsy technology, an innovative non-invasive cancer test that looks for tumor cells and pieces of tumor cells DNA circulating in the blood. The note explores the development of liquid biopsy as an alternative to other cancer screening methods and outlines the market landscape, impact on outcomes, leading companies, and future potential of the technology.
Learning ObjectiveThis case is designed to help students explore how a new innovation has the potential to reshape the existing cancer screening market. Students will acquire background on cancer statistics, screening, and treatment methods, and evaluate the go-to-market potential of liquid biopsy relative to other screening alternatives.
This material is available for download by current Stanford GSB students, faculty, and staff, as well as Stanford GSB alumni. For inquires, contact the Case Writing Office.